Latest Tyrosine kinase inhibitors Stories

University of Colorado-developed treatment effective in Phase 2 Trials in a biomarker-selected group of patientsA combination therapy for treating cancer discovered at the University of Colorado Cancer Center showed improved survival rates in patients with advanced non-small cell lung cancer (NSCLC), according to results presented today from a double-blind, placebo-controlled phase 2 trial run by Syndax Pharmaceuticals. The phase 2 results show that the combination of entinostat (Syndax's...

(IVANHOE NEWSWIRE)-- Combining epigenetic therapy and molecular targeted therapy has shown promising results for combating advanced lung cancer.Epigenetic therapy is designed to control the expression of good and bad genes that influence the development of resistance to targeted therapies. This study, called ENCORE 401, evaluates whether entinostat, a novel epigenetic therapy that is given orally, can be used to delay or overcome the resistance to erlotinib, a drug used to treat patients with...

Chronic myeloid leukemia (CML) was transformed from a fatal disease to a chronic condition by the development of a drug known as imatinib, which targets the protein that drives this disease (BCR-ABL). However, imatinib does not cure patients, they must take the drug lifelong, as disease recurs if they stop taking it. This is because imatinib does not kill all the CML cells; some, which are known as CML stem cells, persist. A key to therapeutically targeting CML stem cells is knowing whether...

A new study shows that a combination of epigenetic therapy and molecular targeted therapy has promising results at combating advanced lung cancer according to research presented at the 2010 Chicago Multidisciplinary Symposium in Thoracic Oncology. This symposium is co-sponsored by the American Society for Radiation Oncology (ASTRO), the American Society of Clinical Oncology (ASCO), the International Association for the Study of Lung Cancer (ISLAC) and The University of Chicago.Epigenetics...

RIDGEFIELD, Conn., Dec. 9, 2010 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. announced that new data from a subgroup analysis of the phase IIb/III LUX-Lung 1 trial show that afatinib (BIBW 2992) reached a four-fold extension (4.4 months vs. 1.0 month for placebo) in progression-free survival (PFS) in advanced non-small cell lung cancer (NSCLC) patients most likely to have an epidermal growth factor receptor (EGFR) mutation.(1) The updated LUX-Lung 1 data will be presented at...

WALTHAM, Mass., Dec. 9, 2010 /PRNewswire/ -- Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, announces clinical results from ENCORE 401, a double-blind, placebo-controlled phase 2 trial, in patients with advanced non-small cell lung cancer (NSCLC). The results show that there was a survival advantage in the subset of patients with elevated E-cadherin (a molecular marker of epithelial tumors) receiving entinostat in combination with erlotinib (Tarceva®). "The...

Drug also acts against chronic myeloid leukemia with untreatable T135I mutationA new drug appears to help chronic myeloid leukemia patients who are out of treatment options after first- and second-line drugs have failed them or because their cancer cells have a mutation that makes them resistant from the start, researchers reported at the 52nd Annual Meeting of the American Society of Hematology.In a Phase I clinical trial, the drug ponatinib produced major or complete hematologic responses...

Over the past decade, significant advances have been made in the treatment of leukemia through the ongoing development of gene-based targeted therapies. Research that will be presented today at the 52nd Annual Meeting of the American Society of Hematology provides greater understanding of the optimal use of several BCR-ABL inhibitors for the treatment of acute lymphoblastic leukemia (ALL) and chronic myeloid leukemia (CML), and how a new gene target functions for several myeloid...

NEW YORK, Dec. 6, 2010 /PRNewswire/ -- See video from Novartis at: http://www.thenewsmarket.com/Releases/StoryDetailPage.aspx?GUID=b76c2552-3cd3-4727-8f46-ef825bcb66d4# Novartis announced 24-month data showing that Tasigna® (nilotinib) continues to surpass Glivec® (imatinib)* in the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase1. These new data, from the first Phase III comparison of the two oral...

NEW YORK, Dec. 6, 2010 /PRNewswire/ -- Pfizer Inc. (NYSE: PFE) announced today that a significantly higher proportion of patients with newly diagnosed chronic myeloid leukemia who were treated with bosutinib (39 percent) experienced a major molecular response (MMR), a secondary endpoint, compared with patients treated with imatinib (26 percent) in the intent-to-treat (ITT) population (p=0.002). However, the study did not meet its primary endpoint of superior complete cytogenetic response...